Label: RIVASTIGMINE patch, extended release
-
NDC Code(s):
70771-1949-1,
70771-1949-7,
70771-1950-1,
70771-1950-7, view more70771-1951-1, 70771-1951-7
- Packager: Zydus Lifesciences Limited
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated November 17, 2025
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
-
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 70771-1949-7
Rivastigmine
Transdermal System
Each System Delivers 4.6 mg/24 hours
For Transdermal Use Only.
Contains 30 systems
NDC 70771-1950-7
Rivastigmine
Transdermal System
Each System Delivers 9.5 mg/24 hours
For Transdermal Use Only.
Contains 30 systems
NDC 70771-1951-7
Rivastigmine
Transdermal System
Each System Delivers 13.3 mg/24 hours
For Transdermal Use Only.
Contains 30 systems
-
INGREDIENTS AND APPEARANCE
RIVASTIGMINE
rivastigmine patch, extended releaseProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70771-1949 Route of Administration TRANSDERMAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength RIVASTIGMINE (UNII: PKI06M3IW0) (RIVASTIGMINE - UNII:PKI06M3IW0) RIVASTIGMINE 4.6 mg in 24 h Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) LIGHT MINERAL OIL (UNII: N6K5787QVP) POLYISOBUTYLENE (1100000 MW) (UNII: FLT10CH37X) POLYISOBUTYLENE (55000 MW) (UNII: TQ77WR8A02) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:70771-1949-7 30 in 1 CARTON 03/06/2019 1 NDC:70771-1949-1 24 h in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA206318 03/06/2019 RIVASTIGMINE
rivastigmine patch, extended releaseProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70771-1950 Route of Administration TRANSDERMAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength RIVASTIGMINE (UNII: PKI06M3IW0) (RIVASTIGMINE - UNII:PKI06M3IW0) RIVASTIGMINE 9.5 mg in 24 h Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) LIGHT MINERAL OIL (UNII: N6K5787QVP) POLYISOBUTYLENE (1100000 MW) (UNII: FLT10CH37X) POLYISOBUTYLENE (55000 MW) (UNII: TQ77WR8A02) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:70771-1950-7 30 in 1 CARTON 03/06/2019 1 NDC:70771-1950-1 24 h in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA206318 03/06/2019 RIVASTIGMINE
rivastigmine patch, extended releaseProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70771-1951 Route of Administration TRANSDERMAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength RIVASTIGMINE (UNII: PKI06M3IW0) (RIVASTIGMINE - UNII:PKI06M3IW0) RIVASTIGMINE 13.3 mg in 24 h Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) LIGHT MINERAL OIL (UNII: N6K5787QVP) POLYISOBUTYLENE (1100000 MW) (UNII: FLT10CH37X) POLYISOBUTYLENE (55000 MW) (UNII: TQ77WR8A02) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:70771-1951-7 30 in 1 CARTON 03/06/2019 1 NDC:70771-1951-1 24 h in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA206318 03/06/2019 Labeler - Zydus Lifesciences Limited (918596198) Establishment Name Address ID/FEI Business Operations Zydus Lifesciences Limited 650461283 ANALYSIS(70771-1949, 70771-1950, 70771-1951) , MANUFACTURE(70771-1949, 70771-1950, 70771-1951)